Synovio Therapeutics

Drug Candidate for Osteoarthritis Therapy

Health Tech & Life Sciences

Active

Pre-Seed Founded 2025

Website ↗

Total raised

—

Last: Pre-Seed 2025-09

Stage

Pre-Seed

Founded

2025

Headcount

—

Sector

Health Tech & Life Sciences

About

Synovio Therapeutics develops a novel small molecule, Fenchone 1D, a specific agonist to the CB2 receptor as a drug candidate for Osteoarthritis therapy.

Funding history · 1 round · — total

2025-09

Pre-Seed Undisclosed

Sectors & technology

Primary sector

Health Tech & Life Sciences

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development

Target customers

Healthcare & Life SciencesLife SciencesPharmaceuticals

Business model

B2C

Name	Synovio Therapeutics
Slug	synovio-therapeutics
Type	Israeli Startup
Founded	2025
HQ country	IL
Primary sector	[object Object]
Sectors	[object Object], [object Object], [object Object]
Business models	B2C
Target customers	[object Object], [object Object], [object Object]
Status	active
Current stage	Pre-Seed
Public stage	Pre-Seed
Total raised (USD)	0
Last round	Pre-Seed (2025-09)
Website	https://synoviotx.com/

Synovio Therapeutics

About

Funding history · 1 round · — total

Sectors & technology